Article Figures & Data
Figures
- Fig 1.
Tumor contrast-enhancement patterns in AG. Postcontrast T1-weighted images depict the nodular (largest focal diameter of ≤1.5 cm), patchy (largest focal diameter of >1.5 cm), and ringlike (cystic necrosis with peripheral enhancement) enhancement patterns.
- Fig 2.
Constitution of tumor contrast enhancements between AG accompanied by mutant or wild type IDH1. The difference in contrast-enhancement rate (asterisk) between tumors from patients with mutant and wild type IDH1 was significant (P < .001). There was no significant difference in enhancement-pattern distribution between tumors from patients with mutant and wild type IDH1 (P = .135). CE indicates contrast enhancement.
- Fig 3.
Kaplan-Meier plots of the series of 216 patients with AG showing the association between the PFS and OS according to combined IDH1 status and tumor contrast enhancement. Mutant IDH1 with no contrast enhancement predicts better survival (PFS, P = .038; OS, P = .043). mut indicates mutant; wt, wild type.
- Fig 4.
Kaplan-Meier plots showing that the tumor contrast enhancement pattern enabled stratification of the PFS and OS of patients with mutant IDH1 (PFS, P = .022; OS, P = .029). Meanwhile, Kaplan-Meier plots show that the tumor contrast-enhancement pattern did not enable stratification of the PFS and OS of patients with wild type IDH1 (PFS, P = .896; OS, P = .842).
Tables
Characteristics IDH1 Status P Valuea Total (n = 216) Mutant (n = 84) Wild Type (n = 132) Age (yr) Median (range) 44 (18–87) 43 (18–71) 45 (18–87) 50 or older/50 or younger 77:139 23:61 54:78 .043 Sex Male/female 135:81 49:35 86/46 .313 KPS ≥80/<80 181/35 78/6 103/29 .004 Contrast enhancement Yes/no 173/43 57/27 116/16 <.001 Pattern of enhancement Nodular/patchy/ringlike 26/62/85 9/14/34 17/48/51 .084 Extent of resection GTR/<GTR 123/93 56/28 67/65 .021 Histopathology AA/AO/AOA 57/44/115 16/20/48 41/24/67 .135 Note:—AA indicates anaplastic astrocytomas; AO, anaplastic oligodendrogliomas; AOA, anaplastic oligoastrocytomas.
↵a Results of the χ2 test.
Characteristic PFS OS P Value HR 95% CI P Value HR 95% CI Age 50 yr or older <.001 1.813 1.318–2.494 .007 1.729 1.134–2.421 Sex (male) .215 0.873 0.695–1.064 .415 0.914 0.612–1.283 Preoperative KPS < 80 .004 2.603 1.154–3.548 .002 2.872 1.270–3.341 Enhancement .570 1.200 0.641–2.247 .625 1.187 0.596–2.365 Enhancement pattern .150 1.107 0.964–1.271 .247 1.902 0.941–1.266 <GTR/GTR .001 1.734 1.237–2.429 <.001 1.926 1.346–2.758 Histopathology .086 0.855 0.715–1.022 .054 0.789 0.654–1.002 IDH1 wild type .002 2.364 1.362–4.098 .004 2.688 1.231–4.717 Predictor P Valuea HR 95% CI PFS Age 50 yr or older .018 1.857 1.111–3.106 Preoperative KPS < 80 .015 2.158 1.179–3.471 <GTR .028 1.598 1.053–2.597 IDH1 wild type .004 2.277 1.303–3.968 OS Age 50 yr or older .016 1.431 1.342–2.434 Preoperative KPS < 80 .026 1.836 1.087–3.402 <GTR .023 1.488 1.210–2.432 IDH1 wild-type .002 2.463 1.389–4.386 ↵a Cox proportional hazard regression analyses. A P value of .05 denoted significance.
Jump to section
Related Articles
Cited By...
- Does Blood-Brain Barrier Disruption Define the Glioma Extracellular Metabolome?
- Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts
- Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas
- MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication